Keyword: Nektar Therapeutics
Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.
Nektar Therapeutics could join the growing list of biotechs opting for a takeover, according to a report that it is exploring strategic options.
UNC scientists unraveled the structure of an opioid receptor, which could allow for the design of painkillers that do not cause side effects.
CSO Hayden will leave as Teva restructures, Bayer R&D reorg sees Moeller in and Busch out for Shire, Shire and Biogen get experienced CFOs.
Just days after their lead drug-device combination was voted down by FDA advisors, Nektar and Bayer were hit by a phase 3 failure in another program.
A University of Edinburgh-led team has uncovered a mechanism in MS that prevents regulatory T cells—which prevent autoimmune activity—from developing.
Mebias presented rat data showing its mu opioid drugs could become a weapon in the scramble to combat the opioid epidemic.
The outlay gives Lilly the rights to a drug designed to treat autoimmune diseases by boosting the number and activity of regulatory T cells.
Check out Friday's dose of biotech's news of note.
Check out the rest of Tuesday's news of note.